804, 322 - 11 AVENUE SW, CALGARY, A0
Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics Biotech Engages Baker Tilly as New Independent Auditor
Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Q2
Q1
FY 2025
Annual and Transition Report of Foreign Private Issuers
Administrative Withdrawal
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to a Registration Statement for Securities of Certain Canadian Issuers